Tenecteplase
TNKase
Action
Intravenous thrombolytic agent. Bioengineered plasminogen activator, similar to tissue plasminogen activator.
Status
Approved 6/2000 by the U.S. Food and Drug Administration for the treatment of acute myocardial infarction (AMI). US stroke trials announced 9/2000.
Trial(s)


|